de la Torre Cristina, Ceña Valentín
Unidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Almansa, 14, 02006 Albacete, Spain.
CIBERNED, Instituto de Salud Carlos III, 28031 Madrid, Spain.
Pharmaceutics. 2018 Oct 17;10(4):190. doi: 10.3390/pharmaceutics10040190.
Alzheimer's disease (AD) is one of the main causes of disability and dependency among elderly people. AD is a neurodegenerative disorder characterized by a progressive and irreversible cognitive impairment, whose etiology is unclear because of the complex molecular mechanisms involved in its pathophysiology. A global view of the AD pathophysiology is described in order to understand the need for an effective treatment and why nanoparticles (NPs) could be an important weapon against neurodegenerative diseases by solving the general problem of poor delivery into the central nervous system (CNS) for many drugs. Drug delivery into the CNS is one of the most challenging objectives in pharmaceutical design, due to the limited access to the CNS imposed by the blood-brain barrier (BBB). The purpose of this review is to present a comprehensive overview of the use of NPs as delivery systems for therapeutic and diagnostic purposes in models of AD.
阿尔茨海默病（AD）是老年人残疾和依赖的主要原因之一。AD是一种神经退行性疾病，其特征为进行性且不可逆的认知障碍，由于其病理生理学涉及复杂的分子机制，其病因尚不清楚。本文描述了AD病理生理学的整体情况，以便理解有效治疗的必要性，以及为何纳米颗粒（NPs）通过解决许多药物进入中枢神经系统（CNS）时递送不佳的普遍问题，可能成为对抗神经退行性疾病的重要武器。由于血脑屏障（BBB）对进入CNS的限制，药物递送至CNS是药物设计中最具挑战性的目标之一。本综述的目的是全面概述纳米颗粒在AD模型中作为治疗和诊断目的递送系统的应用。
